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It is currently unclear whether the GluN2 subtype
influences NMDA receptor (NMDAR) excitotoxicity.
We report that the toxicity of NMDAR-mediated
Ca2+ influx is differentially controlled by the cyto-
plasmic C-terminal domains of GluN2B (CTD2B) and
GluN2A (CTD2A). Studying the effects of acute
expression of GluN2A/2B-based chimeric subunits
with reciprocal exchanges of their CTDs revealed
that CTD2B enhances NMDAR toxicity, compared to
CTD2A. Furthermore, the vulnerability of forebrain
neurons in vitro and in vivo to NMDAR-dependent
Ca2+ influx is lowered by replacing the CTD of
GluN2B with that of GluN2A by targeted exon
exchange in a mouse knockin model. Mechanisti-
cally, CTD2B exhibits stronger physical/functional
coupling to the PSD-95-nNOS pathway, which
suppresses protective CREB activation. Depen-
dence of NMDAR excitotoxicity on the GluN2 CTD
subtype can be overcome by inducing high levels
of NMDAR activity. Thus, the identity (2A versus 2B)
of the GluN2 CTD controls the toxicity dose-
response to episodes of NMDAR activity.
INTRODUCTION
Sustained elevated levels of extracellular glutamate kill central
neurons (Olney, 1969). This ‘‘excitotoxicity’’ is implicated in
neuronal loss in acute neurological disorders, including stroke,
traumatic brain injury, and chronic disorders including Hunting-
ton’s disease (Berliocchi et al., 2005; Choi, 1988; Fan and
Raymond, 2007; Lau and Tymianski, 2010). A major cause of
glutamate excitotoxicity is inappropriate activity of the NMDA
subtype of glutamate receptor (NMDAR), which mediates
Ca2+-dependent cell death (Choi, 1992; Lipton, 2006). MostNMDARs contain two obligate GluN1 subunits plus two GluN2
subunits (Furukawa et al., 2005), of which there are four
subtypes, GluN2A-D, with GluN2A and GluN2B predominant in
the forebrain (Cull-Candy et al., 2001; Monyer et al., 1994;
Paoletti, 2011; Traynelis et al., 2010). GluN2 subunits have large,
evolutionarily divergent cytoplasmic C-terminal domains (CTDs),
which have the potential to differentially associate with signaling
molecules (Ryan et al., 2008). This compositional diversity raises
the (unresolved) question as to whether the GluN2 subtype
(GluN2A versus GluN2B) differentially influences the toxicity of
Ca2+ influx through NMDARs. There is evidence that GluN2B-
and GluN2A-containing NMDARs are both capable of mediating
excitotoxicity (Graham et al., 1992; Lau and Tymianski, 2010;
von Engelhardt et al., 2007); however, whether they do so with
differing efficiency or mechanisms is unclear.
In answering questions relating to subunit-specific function
(including excitotoxicity), it is becoming clear that pharmacolog-
ical approaches are of limited use, given the tools currently avail-
able (Neyton and Paoletti, 2006). Although GluN2B-specific
antagonists are highly selective and have demonstrated a role
for GluN2B-containing NMDARs in excitotoxicity (Liu et al.,
2007), attempts to study the role of GluN2A (Liu et al., 2007)
employed a mildly selective GluN2A-preferring antagonist
(NVP-AAM007) at a concentration shown by others to antago-
nize GluN2B-containing NMDARs (Berberich et al., 2005;
Frizelle et al., 2006; Martel et al., 2009; Neyton and Paoletti,
2006; Weitlauf et al., 2005), rendering some of the findings
hard to interpret. Moreover, the less-controllable conditions in
an intact brain render a weakly selective competitive antagonist,
such as NVP-AAM007, of limited value for in vivo studies.
Another important issue is that receptors can exist in a trihetero-
meric form that contains both a GluN2A and a GluN2B subunit
(Hatton and Paoletti, 2005; Rauner and Ko¨hr, 2011), where the
role of each subunit cannot be established using currently avail-
able pharmacological tools.
Additional problems in relating function to GluN2 subunit
composition include their different spatiotemporal expression
profiles. For example, in younger neurons, GluN2B is predomi-
nant and as such may mediate excitotoxicity simply becauseNeuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc. 543
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The GluN2 CTD Subtype Controls Excitotoxicitymost NMDARs are GluN2B-containing. Moreover, GluN2B- and
GluN2A-containing NMDARs may be enriched at extrasynaptic
and synaptic sites, respectively (Groc et al., 2006; Martel et al.,
2009; Tovar and Westbrook, 1999, but see Harris and Pettit,
2007; Thomas et al., 2006). Since receptor location may be
a determinant of excitotoxicity irrespective of subunit composi-
tion (Hardingham and Bading, 2010), a location-dependent
effect may be misinterpreted as a subunit-specific effect.
We have eschewed pharmacocentric approaches in favor of
molecular genetics to determine whether equivalent levels of
Ca2+ influx through GluN2A- and GluN2B-containing NMDARs
differentially affect neuronal viability. We hypothesized that any
differences would be due to their large CTDs because this is
the primary area of sequence divergence, as well as being the
part of GluN2 known to bind intracellular signaling/scaffolding
proteins (Ryan et al., 2008). By studying signaling from wild-
type and chimeric GluN2A/2B subunits, using both acutely ex-
pressed subunits as well as a mouse knockin model, we find
that the presence of the CTD2B in an NMDAR renders Ca2+ influx
through this receptor more toxic than the presence of CTD2A.
This difference is observed in vivo as well as in vitro and is attrib-
utable in part to enhanced physical/functional coupling of CTD2B
to the PSD-95/nNOS signaling cassette, which suppresses pro-
survival CREB-mediated gene expression, rendering neurons
vulnerable to excitotoxic cell death.
RESULTS
TheCTDs of GluN2B andGluN2ADifferentially Influence
Excitotoxicity Independent of the Identity of the Rest of
the Subunit
We wanted to investigate whether the subtype of GluN2 CTD
influences the excitotoxicity of a given amount of NMDAR-medi-
ated ion flux. We created constructs encoding chimeric recep-
tors based on GluN2B and GluN2A but with their respective
CTDs replaced (denoted as CTR) with each other’s (GluN2-
B2A(CTR) andGluN2A2B(CTR), respectively, Figure 1A). In rat hippo-
campal neurons, we first expressed either wild-type GluN2BWT
or GluN2B2A(CTR), at a developmental stage where endogenousFigure 1. The GluN2BC-Terminal Domain Promotes NMDAR-Mediated
(A) Schematic and linear representation of GluN2A, GluN2B, and the chimeric
Constructs encoding these subunits were expressed in hippocampal neurons. AT
M1-M4, intramembranous domains.
(B) Acute expression of GluN2BWT or GluN2B2A(CTR) has a similar effect on NMD
constructs (plus eGFP marker) and whole-cell steady-state NMDAR-mediated cu
throughout) were compared to control-transfected neurons (b-globin, n = 12–14 c
Responses, here and throughout, were measured at 48 hr posttransfection. Mea
(C) Expression of the subunits described in (A) does not alter the overall proport
example trace of NMDAR-mediated currents before (whole cell) and after synap
dures for details.
(D) GluN2BWT expression renders neurons more vulnerable to an excitotoxic insu
level of toxicity (*p < 0.05; n = 7; 150–200 cells analyzed per condition).
(E) Example pictures of (D) showing transfected cells with the relevant plasmid
neurons before NMDA treatment. Red/blue arrows in the ‘‘posttreatment’’ panel
(F) Expression of GluN2AWT or GluN2A2B(CTR) enhances NMDAR currents to simi
*p < 0.05 (t test comparison to control-transfected neurons).
(G) NMDA-induced toxicity is significantly higher in GluN2A2B(CTR)-transfected ne
See also Figure S1.NMDARs are overwhelmingly GluN2B-containing (Martel et al.,
2009). Expression of GluN2BWT or GluN2B2A(CTR) both enhanced
whole-cell currents to a similar level (Figure 1B) and did not
differentially affect the proportion of extrasynaptic NMDARs
(Figure 1C), as assessed by the ‘‘quantal block’’ method of
irreversibly blocking synaptically located NMDARs (Papadia
et al., 2008). Thus, any differential CTD-specific effects on exci-
totoxicity can be studied without the complicating factor of
altered NMDAR location, which itself influences survival/death
signaling via mechanisms that are likely to be independent of
GluN2 subtype (Hardingham and Bading, 2010; Martel et al.,
2009; Papadia et al., 2008).
We next studied whether expression of GluN2BWT or
GluN2B2A(CTR) had different effects on vulnerability to excitotox-
icity. NMDA (20 mM) was applied for 1 hr to neurons transfected
with vectors encoding either GluN2BWT, GluN2B2A(CTR) or control
vector, and neuronal death was assessed 24 hr later. GluN2BWT
strongly increased the level of cell death compared to the
control, consistent with NMDAR currents being higher (Figures
1D and 1E). However, expression of GluN2B2A(CTR) caused
a significantly lower enhancement of cell death than GluN2BWT
(Figures 1D and 1E), despite NMDAR currents being equal (Fig-
ure 1B), suggesting that CTD2B promotes cell death better than
CTD2A. The same result was found when the experiment was
repeated in DIV18 neurons (see Figure S1A available online),
indicating that the differential effect of CTD2B versus CTD2A on
cell death also holds true in more mature neurons.
To further investigate the differential CTD subtype effects on
excitotoxicity, we compared NMDAR-dependent cell death in
neurons expressing GluN2AWT and GluN2A2B(CTR). Expression
of GluN2AWT and GluN2A2B(CTR) did not differentially affect the
proportion of extrasynaptic NMDARs (Figure 1C) and caused
similar increases in NMDAR currents (Figure 1F); although,
because of the lower affinity of GluN2A for NMDA, the increases
were smaller than for the GluN2B-based constructs (Figure 1B).
We found that neurons expressing GluN2A2B(CTR) were signifi-
cantly more vulnerable to NMDA-induced excitotoxicity than
GluN2AWT-expressing neurons (Figure 1G). Thus, for a given
amount of NMDAR-mediated current, the presence of CTD2BToxicity When Linked to Either Channel Portion of GluN2B or GluN2A
subunits in which the C-terminal domain (CTD) has been replaced (CTR).
D, amino-terminal domain; S1-S2, extracellular ligand-binding domains (LBD);
A-induced whole-cell currents. Neurons were transfected with the indicated
rrents evoked by 20 mM NMDA (and normalized to cell capacitance, here and
ells per construct) * p < 0.05 (t test comparison to control-transfected neurons).
n ± SEM shown here and throughout the figure.
ion of extrasynaptic NMDARs (n = 5–10 cells for each construct). Right shows
tic NMDAR blockade (extrasynaptic). See Supplemental Experimental Proce-
lt (20 mM NMDA for 1 hr), but replacing the CTD to that of GluN2A reduces the
(+eGFP) pre- and post-NMDA treatment. White arrows indicate transfected
s indicate dead/live cells, respectively.
lar levels compared to globin-expressing cells (n = 10–11 cells per construct).
urons than with GluN2AWT (*p < 0.05; n = 8).
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The GluN2 CTD Subtype Controls Excitotoxicitypromotes neuronal death better than CTD2A, regardless of
whether they are linked to the channel portion of GluN2A or
GluN2B. This result illustrates the independent influence of the
identity of the CTD on excitotoxicity, acting in addition to the
influence of the identity of the rest of the channel on downstream
signaling events (e.g., because of different channel kinetics and
ligand binding properties).
A Mouse Knockin Model Reveals the Influence of the
GluN2 CTD Subtype In Vitro and In Vivo
We next investigated the importance of the GluN2 CTD subtype
by an independent approach: a genetically modified ‘‘knockin’’
mouse in which the protein coding portion of the C-terminal
exon ofGluN2B (encoding over 95%of the CTD) was exchanged
for that of GluN2A (GluN2B2A(CTR); Figure 2A; see Supplemental
Experimental Procedures). The 30UTR of GluN2B, which also
forms part of the C-terminal exon, was unchanged apart from
a 61 bp insertion at its beginning (a remnant of the excision of
a neomycin resistance selection cassette). We wanted to deter-
mine whether equivalent Ca2+ influx through GluN2B-containing
and GluN2B2A(CTR)-containing NMDARs would result in different
levels of neuronal death. We studied DIV10 cultured cortical
neurons from GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) littermates.
These cultures exhibited similar levels of basal viability and
levels of synaptic connectivity and strength, as measured by
mini EPSC frequency/size, spontaneous EPSC frequency, and
AMPA receptor currents (Figures S2A–S2D), as well as unaltered
cell capacitance (Figure S2E).
Whole-cell and extrasynaptic NMDAR currents in both
GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) neurons were found to be
similarly sensitive to the GluN2B-specific antagonist ifenprodil.Figure 2. Replacement of the GluN2B C-Terminal Domain with that o
Excitotoxicity in Mouse Cortical Neurons
(Ai) (Left) Linear representations of the GluN2A and GluN2B genes and of the
C-terminal exon of GluN2B (867G to 1482V) was replaced with that of GluN2A (86
illustrating the location of the genotyping primers. Note that a common reverse pr
with a forward primer specific for either the GluN2B (primer ‘‘A’’) or GluN2A CTD
heterozygotes, and homozygous knockin mice.
(Aii) (Left) Cartoon illustrating the gene products of GluN2A, GluN2BWT, and Gl
extracts obtained from GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) cortical neurons a
N-terminal antibody picks up both GluN2BWT and GluN2B2A(CTR), an antibody spe
for the CTD of GluN2A picks up GluN2B2A(CTR).
(B) The effect of ifenprodil (3 mM) on total and extrasynaptic NMDAR currents was
cells per genotype [total]; n = 4 per genotype [extrasynaptic]). NMDAR currents w
throughout). Mean ± SEM shown here and throughout the figure.
(C) The proportion of steady-state extrasynaptic NMDAR currents as a percentag
(see Experimental Procedures; n = 8).
(D) Whole-cell NMDAR responses (evoked by 100 mM NMDA) are lower in GluN2
NMDAR currents in GluN2B2A(CTR)/2A(CTR neurons were expressed as a percenta
(E) Calculation of NMDA concentrations (C1 and C2) predicted to trigger equivale
dose response curves (n = 8 cells for each curve). Relative NMDAR currents ar
neurons.
(F–G) NMDAC1 and NMDAC2 both evoke similar NMDAR currents and increases in
were measured (n = 7–8 cells per condition) and (G) Fluo-3 Ca2+ imaging was pe
experiments.
(H) NMDA-induced cell death is diminished in neurons containing GluN2B2A(
were treated for 1 hr with NMDAC1, NMDAC2, or a high (100 mM) dose of NMD
(GluN2B2A(CTR)/2A(CTR); 13,000–21,000 cells analyzed per treatment per genotype
(I) Example pictures from (H). Scale bar 50 mm.
See also Figure S2.In neurons of both genotypes, we observed a blockade of
around 60% (Figure 2B), indicative of a high (80%) level of
GluN1/GluN2B heterodimeric receptors. Moreover, the propor-
tion of extrasynaptic NMDARs was found to be the same for
GluN2B2A(CTR)/2A(CTR) and GluN2B+/+ neurons (Figure 2C). Thus,
any differential CTD subtype-specific effects on excitotoxicity
could be studied without the potentially confounding factor of
altered NMDAR location. We also investigated whether any
differences in use-dependent run-down of whole-cell NMDAR
currents were observed because this may be relevant to long-
term exposure to NMDA. Having measured baseline whole-cell
NMDAR currents, ten further 10 s applications of NMDA were
applied over a 10 min period. We found no difference in run-
down of steady-state NMDAR currents in GluN2B+/+ and
GluN2B2A(CTR)/2A(CTR) neurons (around 3% per application; Fig-
ure S2F). We also examined NMDAR single-channel properties.
We excised outside-out patches from DIV9 GluN2B+/+ and
GluN2B2A(CTR)/2A(CTR) neurons and measured NMDA-evoked
unitary currents, finding no difference in their mean single-
channel conductance of approximately 50 pS, which is typical
for GluN2B-containing NMDARs (Figure S2G).
Despite the aforementioned similarities, we found one
important difference; whole-cell NMDAR currents in
GluN2B2A(CTR)/2A(CTR) neurons were around 30% lower than
GluN2B+/+ (Figure 2D). Levels of GluN2B protein were lower in
DIV10 GluN2B2A(CTR)/2A(CTR) cortical neurons (Figure S2H) and
in P7 cortical protein extracts (Figure S2I; ruling out the possi-
bility of an in vitro artifact). An explanation for this difference
was foundwhenwe looked at GluN2B2A(CTR) mRNA levels, which
were lower both in DIV10 GluN2B2A(CTR)/2A(CTR) cortical neurons
and in P7 cortical extracts (Figures S2H and S2I). However,f GluN2A in a Mouse Knockin Model Decreases NMDAR-Mediated
knockin mouse line GluN2B2A(CTR), in which the protein coding region of the
6G to 1464V). (Middle) Schematic focusing on the C-terminal exon of GluN2B,
imer (primer ‘‘B’’ within the GluN2B 30 UTR) is used for both reactions, together
(primer ‘‘C’’). (Right) Example of genotyping products obtained in wild-type,
uN2B2A(CTR) (green = GluN2A; red = GluN2B). (Right) Western blot of protein
t DIV8 (when levels of GluN2A are extremely low). Note that, whereas the
cific for the CTD of GluN2B only picks up GluN2BWT, and an antibody specific
measured inGluN2B+/+ andGluN2B2A(CTR)/2A(CTR) DIV10 cortical neurons (n = 9
ere measured at the steady state and normalized to cell capacitance (here and
e of whole-cell currents was analyzed in GluN2B+/+ and GluN2B2A(CTR)/2A(CTR)
B2A(CTR)/2A(CTR neurons (n = 33) compared to GluN2B+/+ (n = 43). Steady-state
ge of those obtained in GluN2B+/+ neurons.
nt NMDAR currents in GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) neurons, based on
e expressed as a percentage of the maximum current obtained in GluN2B+/+
free Ca2+ inGluN2B+/+ andGluN2B2A(CTR)/2A(CTR) neurons. (F) NMDAR currents
rformed where between 90 and 105 cells were analyzed within 3 independent
CTR) compared to GluN2BWT. GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) neurons
A. Cell death was analyzed after 24 hr (*p < 0.05; n = 11 (GluN2B+/+); n = 15
).
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Figure 3. The GluN2 CTD Subtype Determines Excitotoxicity In Vivo
(A) (Upper) GluN2B mRNA levels are not altered in forebrain ofGluN2B+/+ versusGluN2B2A(CTR)/2A(CTR) mice (n = 6). Mean ± SEM shown here and throughout the
figure. (Lower) Example western illustrating equivalent GluN2B protein levels in homogenates of adult forebrains taken fromGluN2B+/+ andGluN2B2A(CTR)/2A(CTR)
mice (t = 0.75; p = 0.51; n = 5). CT/NT = antibody to C/N-terminus of the indicated GluN2 subunit.
(B) Levels of GluN2B protein are not altered in PSD-enriched or non-PSD-enriched fractions derived from synaptosomes prepared from homogenates of
the adult hippocampus of GluN2B+/+ versus GluN2B2A(CTR)/2A(CTR) mice. See Supplemental Experimental Procedures for details; n = 10 GluN2B+/+; n = 5
GluN2B2A(CTR)/2A(CTR).
(C–F) GluN2B2A(CTR)/2A(CTR) mice exhibit smaller NMDA-induced lesion volumes. Brain lesion volumes (mm3) were calculated from hematoxylin-and-eosin-
stained serial sections taken 24 hr following stereotaxic injection of 15 nmol NMDA into the hippocampus. (C–E) Total, hippocampal and thalamic lesion volumes
were calculated (*p < 0.05; ANOVA followed by Tukey’s post hoc test; n = 9 (GluN2B+/+); n = 10;GluN2B2A(CTR)/2A(CTR); n = 5; PBS-treatedGluN2B+/+). (F) (Upper)
Example pictures illustrating NMDA-induced damage in the hippocampus. White dashes indicate the boundary of the lesioned areas, identified by parenchymal
pallor and vacuolation, andmorphological neuronal changes (shrunken, triangulated nuclei and cytoplasm, eosinophilic neurons). Black boxes in the upper panel
are shown in higher magnification in the lower panel to illustrate the lesion boundary in greater detail in the NMDA-injected mice. Upper and lower scale bars are
250 and 50 mm, respectively.
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The GluN2 CTD Subtype Controls Excitotoxicitythis decrement appeared to be a developmental-stage-depen-
dent effect because by adulthood, levels of forebrain GluN2B
mRNA (Figure 3A) and protein (p = 0.51, n = 5,5) were unaltered548 Neuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc.inGluN2B+/+ versusGluN2B2A(CTR)/2A(CTR) mice. We hypothesize
that GluN2B2A(CTR), compared towild-typeGluN2B,may be tran-
scribed, processed, or exported slightly less efficiently, which
Neuron
The GluN2 CTD Subtype Controls Excitotoxicitymanifests itself in a mRNA decrement in development when
expression of many genes, including those encoding NMDAR
subunits, is changing rapidly.
To compare the effects of equivalent NMDAR activity in
GluN2B2A(CTR)/2A(CTR) and GluN2B+/+ neurons, we needed to
adjust the concentration of applied NMDA to compensate for
the lower currents in GluN2B2A(CTR)/2A(CTR) neurons. A NMDA
dose-response curve for both GluN2B2A(CTR)/2A(CTR) and
GluN2B+/+ neurons revealed no difference in their EC-50 s (Fig-
ure S2J). Based on these NMDA dose-responses, we predicted
that an application of 17 and 21 mMNMDA toGluN2B+/+ neurons
would induce the same current as an application of 30 and
50 mM, respectively, toGluN2B2A(CTR)/2A(CTR) neurons (Figure 2E).
This was then confirmed experimentally; application of 17 and
30 mMNMDA (hereafter NMDAC1) applied to GluN2B
+/+ neurons
and GluN2B2A(CTR)/2A(CTR) neurons, respectively, induced equiv-
alent currents (Figure 2F), as did application of the higher pair of
NMDA concentrations: 21 and 50 mMNMDA (hereafter NMDAC2)
applied toGluN2B+/+ neurons andGluN2B2A(CTR)/2A(CTR), respec-
tively (Figure 2F). Given that NMDAR-dependent excitotoxicity is
predominantly Ca2+-dependent, we next studied the intracellular
Ca2+ elevation triggered by NMDAC1 and NMDAC2. Treatment
with NMDAC1 caused similar Ca
2+ loads in GluN2B2A(CTR)/2A(CTR)
and GluN2B+/+ neurons, as did NMDAC2 (Figure 2G).
Satisfied that these doses of NMDA elicit equivalent NMDAR-
dependent currents and Ca2+ loads, we next studied their effects
on neuronal viability. Strikingly, we found that NMDAC1 and
NMDAC2 both promoted more death in GluN2B
+/+ neurons
than inGluN2B2A(CTR)/2A(CTR) (Figures 2H and 2I). Thus, swapping
the GluN2B CTD for that of GluN2A in the mouse genome
reduces the toxicity of NMDAR-dependent Ca2+ influx. This is
in agreement with our studies based on the overexpression of
GluN2A/2B-based wild-type and chimeric subunits (Figure 1),
thus confirming the importance of the CTD subtype by two
independent approaches. We also performed a similar set of
experiments in DIV18 neurons. Because there remained a differ-
ence in whole-cell currents (around 25%), we again generated
NMDAR current dose-response curves to allow us to pick pairs
of NMDA concentrations (15 and 20 mM; 30 and 40 mM) which
would trigger equivalent currents (Figure S2K). Consistent with
our observations at DIV10, we once again saw increased
NMDA-induced death in GluN2B+/+ neurons compared to
GluN2B2A(CTR)/2A(CTR) neurons experiencing equivalent levels of
NMDAR activity (Figure S2L).
We next wanted to determine whether maximal levels of
neuronal death could be achieved in neuronal populations
devoid of CTD2B if NMDAR activity were high enough. We
treated GluN2B2A(CTR)/2A(CTR) neurons with a high dose
(100 mM) of NMDA and found that this triggered near-100%
neuronal death, as it also did in GluN2B+/+ neurons (Figures 2H
and 2I). Thus, the influence of excitotoxicity on the GluN2 CTD
subtype is abolished when insults are very strong.
In the adult mouse forebrain, GluN2B and GluN2A are the
major GluN2 NMDAR subunits (Rauner and Ko¨hr, 2011; Sheng
et al., 1994), raising the question as to whether the GluN2 CTD
subtype (2A versus 2B) influences excitotoxicity in the adult
forebrain in vivo. As stated above, adult forebrain GluN2B
(protein and mRNA) levels are unaltered in GluN2B+/+ versusGluN2B2A(CTR)/2A(CTR) mice (Figure 3A). We also specifically
studied GluN2B levels in isolated protein fractions enriched
in synaptic and peri/extrasynaptic NMDARs, following an
established protocol (Milnerwood et al., 2010). Briefly, a synapto-
somal preparation was made from the hippocampi of adult
GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) mice. This prep was then
split into a Triton-soluble ‘‘non-PSD enriched’’ fraction including
extrasynaptic NMDARs, plus a Triton-insoluble (but SDS-
soluble) ‘‘PSD-enriched’’ fraction containing synaptic NMDARs.
We found no differences in the levels of GluN2B between
GluN2B+/+ and GluN2B2A(CTR)/2A(CTR) hippocampi with regard to
either total homogenate, ‘‘Non-PSD enriched’’ fraction, or
‘‘PSD-enriched’’ fraction (Figure 3B). This biochemical data is
in agreement with observations that the NMDAR:AMPAR
current ratios in evoked EPSCs measured at holding potentials
of 80 and +40 mV are not altered in adult CA1 pyramidal cells
of GluN2B2A(CTR)/2A(CTR) mutants compared to GluN2B+/+
controls (Thomas O’Dell, personal communication). Moreover,
the decay time constant of NMDAR-mediated EPSCs recorded
at +40 mV in GluN2B2A(CRT)/2A(CTR) mutants was found to be
indistinguishable from GluN2B+/+ controls (Thomas O’Dell,
personal communication), indicative of a similar GluN2 subunit
composition.
To promote excitotoxic neuronal loss, we stereotaxically in-
jected a small (15 nmol) dose of NMDA into the hippocampus
(just below the dorsal region of the CA1 layer) and quantified
the resulting lesion volume 24 hr later. Consistent with the
position of the injection site, the lesions were centered on the
CA1 subregion, an effect potentially enhanced by the known
vulnerability of this subregion to excitotoxic insults (Stanika
et al., 2010). However the lesion also spread to other hippo-
campal subregions (CA3, dentate gyrus) as well as a small
intrusion into the thalamus. Importantly, analysis revealed
that GluN2B2A(CTR)/2A(CTR) mice exhibited smaller lesion volumes
in the hippocampus and the thalamic region (and smaller overall
lesion volumes) than GluN2B+/+ mice (Figures 3C–3F). Thus, the
GluN2 CTD subtype also influences NMDAR-mediated excito-
toxicity in vivo.
Differential Signaling to CREB Contributes to GluN2
CTD Subtype-Specific Excitotoxicity
We next investigated the mechanistic basis for the observed
GluN2CTD subtype-dependent differences in vulnerability to ex-
citotoxicity. NMDAR-dependent activation of CREB-dependent
gene expression protects against excitotoxicity (Lee et al.,
2005) and can act as a protective response to excitotoxic insults
(Mabuchi et al., 2001). We found that basal levels of CREB
(serine-133) phosphorylation (normalized to total CREB) were
unaltered in GluN2B2A(CTR)/2A(CTR) neurons (118% ± 12%
compared to GluN2B+/+ neurons, p = 0.2). However we found
that in response to treatment with NMDAC1, CREB (serine-133)
phosphorylation was more prolonged in GluN2B2A(CTR)/2A(CTR)
neurons than in GluN2B+/+ neurons, as assayed by western
blot and immunohistochemistry (Figures 4A–4C), and also that
activation of a CRE-reporter gene and the CREB target gene
Adcyap1 was stronger in GluN2B2A(CTR)/2A(CTR) neurons than
GluN2B+/+ (Figures 4D and 4E). These differences did not extend
to all transcriptional events: no differences were seen in theNeuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc. 549
Figure 4. The GluN2 CTD Subtype Influences Excitotoxicity by Differential Coupling to a CREB Shut-Off Pathway
(A) (Left) Quantitation of western blot analysis of phospho (serine-133)-CREB kinetics following NMDAC1 treatment, normalized to total CREB (*p < 0.05;
GluN2B+/+ n = 11; GluN2B2A(CTR)/2A(CTR) n = 12). Mean ± SEM shown here and throughout the figure. (Right) Example blot (relevant samples within a single blot
have been grouped).
(B)Quantitationof immunohistochemical analysisofphospho-CREBkinetics followingNMDAC1 treatment. (*p<0.05; n=7 (GluN2B
+/+); n =4 (GluN2B2A(CTR)/2A(CTR));
200 cells analyzed in each condition, in each repeat.
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The GluN2 CTD Subtype Controls ExcitotoxicityNMDAC1-induced activation of Srxn1, an AP-1 target gene (Sor-
iano et al., 2009), or suppression of the FOXO target gene Txnip
(Al-Mubarak et al., 2009; Figures S3A and S3B). To confirm
whether CREB-dependent gene expression causally influenced
vulnerability to NMDAR-mediated excitotoxicity we utilized the
inhibitory CREB family member ICER which we have previously
confirmed blocks the induction of CRE-mediated gene expres-
sion when expressed in cortical neurons (Papadia et al., 2005).
ICER expression increased levels of NMDAC1-induced death in
both GluN2B2A(CTR)/2A(CTR) and GluN2B+/+ neurons (Figures
4F–4H). However, the effect of ICER on GluN2B2A(CTR)/2A(CTR)
neurons was greater than its effect on GluN2B+/+ neurons (Fig-
ure 4G), indicating that differential CREB activation is a contrib-
uting factor to the observed CTD subtype-dependent control of
excitotoxicity.
One known regulator of CREB phosphorylation is nitric oxide
(NO) which is produced when NMDAR-dependent Ca2+ influx
activates nNOS, recruited to the NMDAR signaling complex via
PSD-95 association with GluN2 subunits (Aarts et al., 2002).
Whereas basal NOS activity can contribute to CREB phosphor-
ylation in dentate granule cells (Ciani et al., 2002), it has been
found to suppress CREB phosphorylation in the hippocampus
(Park et al., 2004; Zhu et al., 2006). Furthermore, nNOS inhibition
or deficiency boosts CREB phosphorylation following stroke
(Luo et al., 2007). Compared to GluN2B2A(CTR)/2A(CTR) neurons,
GluN2B+/+ neurons coupled more strongly to NMDAC1-induced
NO production (Figure 5A), despite nNOS and PSD-95 levels
being the same (Figures S4A and S4B). Moreover, nNOS
inhibition by 7-nitroindazole treatment enhanced CREB phos-
phorylation and CREB-dependent gene expression more
strongly in GluN2B+/+ neurons than GluN2B2A(CTR)/2A(CTR)
neurons, eliminating the CTD-subtype specific differences
(Figures 5D–5F). This may be due to a stronger GluN2-PSD-
95-nNOS coupling because association of GluN2B with PSD-
95 was found to be stronger in P7 cortical extracts from
GluN2B+/+ mice versus GluN2B2A(CTR)/2A(CTR) mice (Figures 5B
and 5C). Moreover, treatment of neurons with TAT-NR2B9c,
which partly uncouples GluN2B from PSD-95 and NO pro-
duction (Aarts et al., 2002), promoted more sustained
CREB phosphorylation and enhanced CRE-reporter activity in
NMDAC1-treated GluN2B
+/+ neurons (Figures 5D–5F), but had(C) Example images relating to (B). At the 30 min time point, phospho-CREB leve
many GluN2B+/+ neurons. Scale bar = 30 mm.
(D) NMDAR-mediated induction of the CREB target gene Adcyap1 is elevated
extracted at 4 hr posttreatment and subject to qPCR-based analysis of Adcyap1 (
(E) NMDAR-mediated induction of CRE-dependent gene expression is elevated in
transfected with a CRE-luciferase reporter plus pTK-renilla control and treated w
normalized to renilla luciferase control (*p < 0.05; n = 11 (GluN2B+/+); n = 12 (Glu
(F) Effect of ICER expression on vulnerability to NMDAR-mediated excitotoxicity in
either ICER1 or control vector (encoding b globin) were treated where indicated w
to track their fate, after which cells were fixed and nuclei DAPI stained. *p < 0.05
expressing neurons with NMDA-treated globin-expressing neurons of that gen
cultures were analyzed; 200–300 cells in total per condition/genotype combinati
(G) ICER has a greater effect on vulnerability to excitotoxicity inGluN2B2A(CTR)/2A(C
levels of NMDA-induced neuronal death ± ICER expression were calculated. *p
(H) Example pictures from (F). White arrows indicate transfected neurons before N
live cells, respectively. Scale bar 50 mm.
See also Figure S3.little effect on these pathways in GluN2B2A(CTR)/2A(CTR) neurons
(with the caveat that TAT-NR2B9c disrupts GluN2B-PSD95
binding at lower concentrations than it does for GluN2A). Thus,
CTD2B couples mores strongly to PSD-95, NO production and
nNOS-dependent CREB inactivation, enhancing vulnerability to
excitotoxicity.
The basis for stronger association of PSD-95 with GluN2BWT
compared to GluN2B2A(CTR) could be due to different sequences
immediately upstream of the conserved C-terminal PDZ ligand.
We generated a chimeric variant of GluN2B in which the final
12 amino acids of its CTD have been replaced by those of
GluN2A (three amino acid differences, GluN2B(2A-PDZ)). Coim-
munoprecipitation studies revealed that GluN2B(2A-PDZ) had
a similar affinity for PSD-95 as GluN2B (Figure S4C), indicating
that immediate upstream sequence differences are not the
basis for differential association of PSD-95 with the CTDs of
GluN2B and GluN2A. Recently, additional PSD-95 interaction
domains have been discovered on internal regions of CTD2B
(1086–1157; Cousins et al., 2009), which could contribute to
the overall affinity of the CTD for PSD-95. The role of these
additional regions in neurons is not yet clear, but could act to
stabilize the primary interaction with the C-terminal PDZ
ligand, or even act independently. Deletion of this region
(creating GluN2BD(1086–1157)) resulted in a small reduction in
PSD-95 association (Figure 5G). Importantly, NMDA-induced
death following overexpression of GluN2BD(1086–1157) in primary
rat hippocampal neurons (as per the assays used in Figure 1)
was significantly lower than in neurons overexpressing
GluN2BWT (Figure 5H), even though whole-cell NMDAR currents
were found to be the same in GluN2BD(1086–1157) as wild-
type GluN2BWT-expressing neurons (Figure 5I), implicating
this region of the CTD in contributing to prodeath NMDAR
signaling.
DISCUSSION
Wehave demonstrated distinct roles for theCTDs of GluN2B and
GluN2A in determining the dose response of NMDAR-mediated
excitotoxicity. CTD2B promotes neuronal death more efficiently
than CTD2A, an effect which is observed regardless of whether
the CTD is tethered to the channel portion of GluN2B or ofls remain high in GluN2B2A(CTR)/2A(CTR) neurons but have returned to baseline in
in GluN2B2A(CTR)/2A(CTR) neurons, compared to GluN2B+/+ neurons. RNA was
normalized to Gapdh; *p < 0.05; n = 5 (GluN2B+/+); n = 4 (GluN2B2A(CTR)/2A(CTR)).
GluN2B2A(CTR)/2A(CTR) neurons, compared toGluN2B+/+ neurons. Neuronswere
ith NMDAC1 for 8 hr, after which CRE firefly reporter activity was assayed and
N2B2A(CTR)/2A(CTR)).
GluN2B+/+ andGluN2B2A(CTR)/2A(CTR) neurons. Neurons expressing eGFP plus
ith NMDAC1. Images of cells were taken before and 24 hr post-NMDA treatment
(indicated comparisons on figure); #p < 0.05 (comparing NMDA-treated ICER-
otype), n = 9 (GluN2B+/+) and n = 11 (GluN2B2A(CTR)/2A(CTR)) NMDAC1-treated
on.
TR) neurons compared to wild-type. From the data in (F), the difference between
< 0.05; n = 9 (GluN2B+/+); n = 11 (GluN2B2A(CTR)/2A(CTR)).
MDA treatment. Red/blue arrows in the ‘‘posttreatment’’ panels indicate dead/
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Figure 5. The GluN2B CTD Couples More Strongly to a PSD-95-nNOS-Mediated CREB Shut-Off Pathway Than that of GluN2A
(A) DAF-FM-based NO assay (see Experimental Procedures) performed on neurons treated with NMDAC1 for 10 min. *p < 0.05; n = 6 (GluN2B
+/+); n = 9
(GluN2B2A(CTR)/2A(CTR)). Mean ± SEM shown here and throughout the figure.
(BandC)GluN2BWTassociatesmorestronglywithPSD-95 thandoesGluN2B2A(CTR).GluN2Bwas immunoprecipitated fromGluN2B+/+(WT)andGluN2B2A(CTR)/2A(CTR)
(2AC) P7 cortical homogenates with a GluN2B N-terminal antibody. The presence of GluN2B and PSD-95 in the immunoprecipitate was analyzed by western blot,
and the ratio of band intensities (PSD:GluN2B) was calculated (* p < 0.05; n = 11 (GluN2B+/+); n = 12 (GluN2B2A(CTR)/2A(CTR)).
(D and E) Western analysis of CREB phosphorylation (normalized to total CREB) in neurons pretreated as indicated with 7-nitroindazole (5 mM) or TAT-NR2B9c
(2 mM) prior to NMDAC1 treatment for 5 or 30min. *, p < 0.05; n = 10 (GluN2B
+/+); n = 8 (GluN2B2A(CTR)/2A(CTR)). #, p < 0.05 t test comparison of the effect of the drug,
compared to the (NMDA-treated) control.
(F) CRE reporter assay carried out as in Figure 4E. *p < 0.05; n = 5 (GluN2B+/+); n = 7 (GluN2B2A(CTR)/2A(CTR)). #, p < 0.05 paired t test comparison of the effect of the
drug, compared to the control.
(G) Deletion of the GluN2B CTD between 1086–1157 lowers GluN2B affinity for PSD-95. HEK cells were transfected with plasmids encoding GluN1, PSD-95, and
GluN2BWT or GluN2BD(1086–1157). After 24 hr, protein was extracted, and the association of GluN2B or GluN2BD(1086–1157) with PSD-95 was studied by coim-
munoprecipitation, using an antibody to the N terminus of GluN2B. Upper, densitometric analysis of the resulting western blot (*, p < 0.05 paired t test; n = 6).
Lower, an example blot.
(H) Deletion of the GluN2B CTD between 1086–1157 lowers GluN2B-mediated excitotoxicity. Neurons were transfected with the indicated GluN2B constructs or
b-globin (plus eGFP marker), and NMDA-induced death was assessed as described in Figure 1D (*p < 0.05 paired t test [n = 8]; 250–300 cells analyzed per
condition).
(I) Acute expression of GluN2BWT or GluN2BD(1086–1157) has a similar effect on NMDA-induced whole-cell currents. Neurons were transfected with the indicated
constructs (plus eGFP marker), and whole-cell steady-state NMDAR-mediated currents evoked by 100 mM NMDA (normalized to cell capacitance) were
compared to control-transfected neurons (b-globin; n = 4).
See also Figure S4.
Neuron
The GluN2 CTD Subtype Controls ExcitotoxicityGluN2A. Moreover, this difference is observed both in the
context of acute chimeric subunit expression in wild-type
neurons, as well as in a knockin mouse where the CTD is swap-552 Neuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc.ped at the genetic level. Using the latter approach, we demon-
strated the influence of the GluN2 CTD subtype in controlling
excitotoxic lesion volume in vivo. We also show that the GluN2
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The GluN2 CTD Subtype Controls ExcitotoxicityCTD subtype’s ability to influence excitotoxicity is overcome
when strong excitotoxic insults are applied.
These findings raise the question as to whether subunit
composition (and CTD identity) underlies the known differential
prodeath signaling from synaptic versus extrasynaptic
NMDARs, or whether it represents an additional factor that
influences excitotoxicity (Hardingham and Bading, 2010).
Although some studies have reported that GluN2B is enriched
at extrasynaptic sites (Groc et al., 2006; Martel et al., 2009; Tovar
and Westbrook, 1999), apparently in favor of the first alternative,
on closer inspection this study, plus published work, favors the
latter alternative. Ca2+ influx dependent on intense trans-
synaptic activation of synaptic NMDARs is well tolerated and
neuroprotective (Hardingham and Bading, 2010; Hardingham
et al., 2002; Le´veille´ et al., 2010; Zhang et al., 2011). In contrast,
similar Ca2+ loads induced by the chronic activation of extrasy-
naptic NMDARs couple preferentially to prodeath pathways
(Dick and Bading, 2010; Dieterich et al., 2008; Hardingham and
Bading, 2010; Hardingham et al., 2002; Ivanov et al., 2006;
Le´veille´ et al., 2008; Wahl et al., 2009; Xu et al., 2009; Zhang
et al., 2007).
At developmental stages where GluN2B-containing NMDARs
dominate at all locations, differential synaptic versus extrasy-
naptic NMDAR signaling is still observed (Hardingham et al.,
2002). Importantly, the strong trans-synaptic activation of
synaptic GluN2B-containg NMDARs is neuroprotective (Martel
et al., 2009; Papadia et al., 2008). Our current study shows that
the identity of the GluN2 CTD profoundly influences excitotoxic-
ity in the context of chronic activation of all (synaptic and
extrasynaptic) NMDARs, scenarios that are likely to exist in
pathological situations such as ischemia, traumatic brain injury,
or glutamate dyshomeostasis triggered by disease-causing
agents. Thus, location/stimulus-specific effects can be un-
coupled from GluN2 subunit-specific effects, suggesting that
subunit/CTD composition represents an additional factor that
determines the level of excitotoxicity following chronic NMDAR
activation. This is further supported by the fact that recent
electrophysiological and immuno-EM studies have shown that
GluN2 subunit composition may not be dramatically different
at synaptic versus extrasynaptic sites (Harris and Pettit, 2007;
Petralia et al., 2010; Thomas et al., 2006). Our observations
that swapping CTD2B for CTD2A has little effect on whether
a subunit ends up at a synaptic or extrasynaptic site is consistent
with the aforementioned studies reporting that subunits do not
have a strong location preference. Any apparent enrichment of
synaptic sites for GluN2A may reflect the fact that GluN2A
upregulation coincides developmentally with increased synapto-
genesis (Liu et al., 2004), or be due to the influence of sequences
outside of the CTD.
That notwithstanding, GluN2B has been reported to be partly
enriched at extrasynaptic locations in neurons (Groc et al., 2006;
Martel et al., 2009; Tovar andWestbrook, 1999), which suggests
that GluN2 subtype effects and location effects may cooperate
to exacerbate excitotoxicity under certain circumstances. Of
note, recent work has revealed a causal role for enhanced
GluN2B-containing extrasynaptic NMDARs in ischemic neuronal
death (Tu et al., 2010). Also, a specific increase in GluN2B-
containing NMDARs in medium-sized spiny striatal neurons,specifically at extrasynaptic locations, contributes to phenotype
onset in a model of Huntington’s disease (Fan et al., 2007;
Milnerwood et al., 2010), where the synaptic/extrasynaptic
NMDAR balance controls mutant Huntingtin toxicity (Okamoto
et al., 2009).
The idea that subunit composition influences excitotoxicity
independently or additively to the influence of receptor location
raises the possibility of a hierarchy of NMDARs when it comes
to promoting excitotoxicity, based on the combination of
composition (2A versus 2B) and location (synaptic versus extra-
synaptic). Whereas strong activation of synaptic GluN2B-
containing NMDARs is well-tolerated and neuroprotective
(Martel et al., 2009; Papadia et al., 2008), the current study raises
the possibility that activation of synaptic GluN2B-containing
NMDARs (but not GluN2A-containing) could augment excitotox-
icity in the context of chronic extrasynaptic NMDAR activation,
for example, through enhanced NO production. This would
explain the antiexcitotoxic effect of TAT-NR2B9c, PSD-95
knockdown, or disrupting the PSD-95-nNOS interface (Aarts
et al., 2002; Cao et al., 2005; Sattler et al., 1999; Soriano et al.,
2008b; Zhou et al., 2010), and the reversal of CTD2B-dependent
CREB inactivation by TAT-NR2B9c and nNOS inhibition (Fig-
ure 5). However, because PSD-95 clusters have been observed
at extrasynaptic sites (Carpenter-Hyland and Chandler, 2006),
colocalizing with extrasynaptic NMDARs (Petralia et al., 2010),
the possibility that extrasynaptic CTD2B also contributes to this
pathway should not be ruled out. Regardless of these issues,
targeting GluN2B-PSD95 signaling to neurotoxic pathways
offers genuine translational potential because it has been
recently shown that stroke-induced damage and neurological
deficits can be prevented in nonhuman primates by the adminis-
tration of TAT-NR2Bc as late as 3 hr after stroke onset (Cook
et al., 2012).
Investigations into why PSD-95 association with GluN2BWT is
stronger than its association with GluN2B2A(CTR) implicated
a previously identified internal region (Cousins et al., 2009) as
a contributing factor, although deleting it had a relatively small
effect on PSD-95 association, indicating that other determinants
may also be relevant. Also, differing affinities of CTD2B and
CTD2A for PSD-95 may be partly due to other factors binding
CTD2A, occluding PSD-95 binding.
It is also possible that signals other than NO underlie the
differential CTD subtype prodeath signaling, or that NO affects
pathways other than CREB. One known NO target is the PI3K-
Akt pathway, which is induced by NMDAR activity and neuro-
protective in this context (Lafon-Cazal et al., 2002; Papadia
et al., 2005). Modest NO levels promote PTEN S-nitrosylation,
boosting Akt activity, whereas excessive NO also S-nitrosylates
Akt itself, inactivating it (Numajiri et al., 2011). We have prelim-
inary evidence that NMDA-induced Akt activation is enhanced
in GluN2B2A(CTR)/2A(CTR) neurons (M.A. Martel and G.E. Hardi-
ngham, unpublished data), and it will be of interest to determine
any role of differential NO production. Also, it would be of
interest to know whether NMDAR signaling to protective
transcriptional responses other than CREB are sensitive to
GluN2 CTD subtype (e.g., Iduna; Andrabi et al., 2011). These,
and other issues surrounding subunit-specific signaling could
benefit from a future systematic analysis of the NMDARNeuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc. 553
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neurons.
EXPERIMENTAL PROCEDURES
Neuronal Culture and Induction of Excitotoxicity
Cortical mouse and hippocampal rat neurons were cultured as described
(Papadia et al., 2008) at a density of between 9 and 13 3 104 neurons per
cm2 from E17.5 mice or E21 rats with neurobasal growth medium supple-
mented with B27 (Invitrogen, Paisley, UK). Stimulations of cultured neurons
were done in most cases after a culturing period of 9–11 days, during which
neurons develop a network of processes, express functional NMDA-type
and AMPA/kainate-type glutamate receptors, and form synaptic contacts.
Other experiments were performed at DIV 18. To apply an excitotoxic insult,
neurons were first placed overnight into a minimal-defined medium (Papadia
et al., 2005) containing 10% MEM (Invitrogen) and 90% salt-glucose-glycine
(SGG) medium (Bading et al., 1993; SGG: 114 mM NaCl, 0.219% NaHCO3,
5.292 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM Glycine,
30 mM Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolarity
325 mosm/l; Papadia et al., 2005). Neurons were then treated with NMDA
(Tocris Bioscience, Bristol, UK) at the indicated concentrations for 1 hr, after
which NMDARs were blocked by adding the antagonist MK-801 (10 mM). After
a further 23 hr, neurons were fixed and subjected to DAPI staining, and cell
death was quantified by counting (blind) the number of shrunken, pyknotic
nuclei as a percentage of the total. For analysis of excitotoxicity in GluN2B+/+
versus GluN2B2A(CTR)/2A(CTR) neurons, approximately 800–1,200 cells were
analyzed per condition, per replicate (repeated across several replicates).
GluN2B-2A(CTR) Knockin Mouse
GluN2B-2A(CTR) knockin mice contain a GluN2B gene in which the protein
coding portion of the C-terminal exon has been replaced with the protein
coding region of the C-terminal exon of GluN2A (C-terminal domain replace-
ment, CTR). The C-terminal exon encodes amino acids 867G to 1482V
(GluN2B) and 866G to 1464V (GluN2A), which represents over 95% of the
CTD, beginning at position 838E (GluN2A) and 839E (GluN2B). All other regions
of the GluN2B gene are unaltered, including the 30UTR, although there remains
a 61 bp insert containing a loxP site located after the STOP codon at the begin-
ning of the 30UTR (a remnant of the excision of the Neo-selection cassette). To
obtain cultured neurons from GluN2B2A(CTR)/2A(CTR) mice, male and female
heterozygous GluN2B+/2A(CTR) mice were mated, and the cortices from indi-
vidual E17.5 mice were cultured as above. See Supplemental Experimental
Procedures for further details.
Transfection and Following the Fate of Transfected Cells
Neuronswere transfected at DIV8 using Lipofectamine 2000 (Invitrogen), using
an established protocol (McKenzie et al., 2005). Transfection efficiency was
approximately 5%. Greater than 99% of eGFP-expressing transfected
neurons were NeuN-positive, and <1% were GFAP-positive (Soriano et al.,
2008a), confirming their neuronal identity. For studying the effects of express-
ing wild-type and chimeric receptors based on GluN2A and GluN2B,
constructs were cotransfected with peGFP (ratio 1:1) to identify transfected
cells. Coexpression at this ratio was confirmed in the case of pRFP (Papadia
et al., 2008). After 48 hr, the transfected neurons were then either subjected
to electrophysiological analysis or their fate following an excitotoxic insult
was studied. Pictures of GFP-expressing neurons were taken on a Leica
AF6000 LX imaging system, with a DFC350 FX digital camera. Using the auto-
mated cell-finder function within the Leica AF6000 software, images of trans-
fected neurons were taken both before and 24 hr after a 1 hr treatment with
NMDA (20 mM). Cell death was assessed by counting the number of surviving
GFP-positive neurons. In the vast majority of cases, death was easily spotted
as an absence of a healthy GFP-expressing cell where one once was. In place
of the cell, there was in most cases (>90%) evidence of death in the form of
fragmented neurites, fluorescent cell debris, and a pyknotic nucleus (Papadia
et al., 2008). This confirmed that the cells were genuinely dying as opposed to
more unlikely scenarios, such as quenching of eGFP fluorescence in a subpop-
ulation of neurons. For each condition, 150–200 neurons were studied over554 Neuron 74, 543–556, May 10, 2012 ª2012 Elsevier Inc.several independent experiments. An identical experimental regime was
employed for studying the influence of ICER expression on vulnerability of
GluN2B2A(CTR)/2A(CTR) and GluN2B+/+ neurons to NMDA-induced excitotoxic-
ity. Neurons were transfected with vectors encoding eGFP and the inhibitory
CREB family member ICER1 (Stehle et al., 1993), or a control vector (encoding
b-globin). We have previously confirmed that ICER1 expression inhibits CRE-
mediated gene expression in neurons (Papadia et al., 2005). The fate of trans-
fected neurons following exposure to NMDA was then studied as described
previously.
Analysis of Extrasynaptic NMDAR Currents
To measure extrasynaptic NMDAR currents, synaptically located NMDARs
were blocked by quantal activation-mediated blockade by MK-801, as previ-
ously described (Martel et al., 2009; Papadia et al., 2008). Briefly, whole-cell
NMDAR currents were recorded (100 mM NMDA, in Mg2+-free and TTX/PTX-
containing recording solution), after which the agonist was washed-out the
recording chamber for 2 min. Irreversible NMDAR open-channel blocker
MK-801 (10 mM; Tocris Bioscience) was then applied for 10 min, effectively
antagonizing NMDARs located at the synapse and experiencing the localized,
quantal presynaptic glutamate release (Martel et al., 2009; Nakayama et al.,
2005). Following the 10 min incubation period, MK-801 was then washed
out (2 min), and the resulting extrasynaptic NMDAR currents were acquired.
Other Procedures
See Supplemental Experimental Procedures for details of genotyping, plasmid
generation, electrophysiological recording conditions, qPCR analysis, Ca2+
imaging, stereotaxic NMDA administration, NO assays, western blotting and
immunofluorescence, co-immunoprecipitation, and equipment settings. All
procedures were authorized under a UKHomeOffice approved project licence
and adhered to regulations specified in the Animals (Scientific Procedures) Act
(1986) and approved by the University of Edinburgh’s Local Ethical Review
Committee. Statistical testing involved a 2-tailed paired Student’s t test. For
studies employing multiple testing, we used a one-way ANOVA followed by
Fisher’s LSD or Tukey’s post hoc test.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
neuron.2012.03.021.
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